Systematic Review of Gemcitabine in the Treatment of Non-small-cell Lung Cancer / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the clinical efficacy,safety and status of gemcitabine for non-small-cell lung cancer (NSCLC) systematically.METHODS:Included studies retrieved from Medline,EMbase,Cancerdit,CBM and CNKI were evaluated by two reviewers alone and cross-checked.The Meta-analyses of studies were conducted using RevMan 4.2.2 software.RESULTS:12 studies containing 1,715 patients with NSCLC were included.12 studies were all reported randomly(RCT).Hidden information and application of blind method in therapy were not reported.Results of meta-analysis indicated that:(1)After chemotherapy reaction rate and the level of median disease development in GP therapy (gemcitabine combined with cisplatin) were higher than in GC therapy (gemcitabine combined with carboplatin) with similar median survival time and strong reaction of digestive tract;(2)Reaction rate;the level of median disease development and median survival time in GP therapy than in EP therapy (etoposide combined with cisplatin) but with strong toxicity in bone marrow;(3)Reaction rate of GP therapy was same to NP therapy (vinorelbine combined with cisplatin) with strong toxicity in bone marrow;(4)Reaction rate,median survival time and one-year survival rate in GP therapy were similar to in gemcitabine alone therapy with intense reaction in digestive tract;(5)Reaction rate in VGP therapy (vinorelbine,gemcitabine combined with cisplatin) was higher than in VG therapy (vinorelbine combined with gemcitabine) with strong toxicity in bone marrow but they had same the level of median disease development and median survival time;(6)Reaction rate,median survival time in DG therapy (gemcitabine combined with taxotere) were higher than in taxotere alone therapy with advanced the quality of life and strong toxicity in bone marrow;(7)Reaction rate,median survival time,the level of median disease development and one-year survival rate in therapy of gemcitabine (50 mg?min-1?30 min,i.v) were similar to that of gemcitabine (10 mg?min-1?150 min,i.v) with intense toxicity in bone marrow.17 cases of related death were reported in all researches.CONCLUSION:Gemcitabine has exact clinical efficacy and causes strong toxicity in bone marrow and reaction in digestive tract.